High Net Worth Advisory Group’s Neurocrine Biosciences NBIX Stock Holding History

High Net Worth Advisory Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$119K	–	434
2022 Q4	$119K	Hold	1,000	–	–	0.05%	233
2022 Q3	$106K	Hold	1,000	–	–	0.05%	235
2022 Q2	$97K	Hold	1,000	–	–	0.04%	242
2022 Q1	$94K	Hold	1,000	–	–	0.03%	258
2021 Q4	$85K	Buy	+1,000	New	+$92K	0.03%	280

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

High Net Worth Advisory Group's NBIX Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 1,000 shares — an estimated $119K sold.

High Net Worth Advisory Group first reported a position in NBIX in Q4 2021 and held it in 5 quarters. The position peaked at $119K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

High Net Worth Advisory Group reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
High Net Worth Advisory Group sold 1,000 Neurocrine Biosciences shares in Q1 2023, an estimated $119K.
High Net Worth Advisory Group first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 5 quarters.
High Net Worth Advisory Group's Neurocrine Biosciences position peaked at $119K in Q4 2022.
486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.